IP Library › Granted Patent US 12662493
Granted Patent B2
US 12662493 · App. 17/424,441 · Granted Jun 23, 2026

Non-immunosuppressive FK506 analogs and use thereof

Inventors: Jun O. Liu (Clarksville, MD); Zhaoli Sun (Perry Hall, MD); Brandon J. Peiffer (Rosedale, MD); Yuefan Wang (Nottingham, MD); Le Qi (Baltimore, MD); Zufeng Guo (Baltimore, MD); Hanjing Peng (Columbia, MD); Ali Ahmadi (Baltimore, MD)
Assignee: The Johns Hopkins University
C07D498/18A61K31/439A61K31/706A61K45/06A61P17/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12662493
App. No.
17/424,441
Granted
Jun 23, 2026
Kind
B2
Abstract

The present invention provides a new class of non-immunosupressive FK506 analogs which are FRBP-selective, small-molecule BMP agonists with modest potency therepeutics for tissue repair and regeneration. Also disclosed herein are methods for making and use of these compounds.

Claims (10)

1 . A non-immunosuppressive compound of formula I:

a or a salt, solvate, or isomer thereof, wherein R is selected from

2 . A composition comprising a non-immunosuppressive compound of formula I:

a or a salt, solvate, or isomer thereof, wherein R is selected from

3 . The composition of claim 2 , further comprising a biologically active agent.

4 . A composition comprising a non-immunosuppressive compound of formula I:

a or a salt, solvate, or isomer thereof, wherein R is selected from

at least one stem cell mobilizer; and a pharmaceutically acceptable carrier.

5 . The composition of claim 4 , wherein the stem cell mobilizer comprises a CXCR4 antagonist.

6 . The composition of claim 5 , wherein the CXCR4 antagonist is AMD3100, TG-0054, or AMD3465.